Replies to post #1697 on Immune Pharmaceuticals Inc (fka IMNPQ)

[Namwons]

Do you mean IMNP will no longer be in the picture?

IMNP would be a shareholder of Cytovia, I predict they would be a minority shareholder even though at the moment they have the global rights to Ceplene. The bigger prize here is gaining control of the combination of HDC/IL2. That will cost Cytovia a lot of money - $100m plus. However it will come with a significant IL2 revenue stream which is how they will attract funding in addition to future revenue from the HDC/IL2 combination in AML.
Pint will also be a minority shareholder. Proleukin is the missing piece in the jigsaw....when you get your head around that you will see where they are going.